Taro Kishi Kenji Sakuma Masakazu Hatano Takenori Okumura Masaki Kato Hajime Baba Nakao Iwata
Neuropsychopharmacology reports 2024年2月
AIM: To update the major depressive disorder (MDD) treatment guidelines of the Japanese Society of Mood Disorders, we conducted a systematic review and pairwise meta-analysis of double-blind, randomized, placebo-controlled trials of available anti...
Yupeng He Masaaki Matsunaga Yuanying Li Taro Kishi Shinichi Tanihara Nakao Iwata Takahiro Tabuchi Atsuhiko Ota
JMIR Formative Research 7 e50193-e50193 2023年11月
Background
In Japan, challenges were reported in accurately estimating the prevalence of schizophrenia among the general population. Retrieving previous studies, we investigated that patients with schizophrenia were more likely to experience poo...
AIM: The present study aimed to examine the association between copy number variations (CNVs) in parkin (PRKN) and schizophrenia (SCZ) and autism spectrum disorder (ASD) in a large case-control sample. METHOD: Array comparative genomic hybridizati...
Journal of psychiatric research 167 132-138 2023年10月
The benefits of serotonin 3 receptor antagonists (5-HT3R-As) in obsessive-compulsive disorder (OCD) treatment remain unclear. Thus, this study aimed to perform a systematic review and a random-effects meta-analysis, including double-blind, randomi...
岩田 仲生 石郷岡 純 Kim Won-Hyoung Yoon Bo-Hyun Lin Shih-Ku Sulaiman Ahmad Hatim Cosca Rowena Wang Lina Suchkov Yury Agarkov Alexey 渡部 恵 松井 智均 佐藤 貴之 井上 善文 樋口 輝彦 Correll Christoph U. Kane John M.
臨床精神薬理 23(3) 295-312 2020年3月
【背景】Blonanserin(BNS)は、統合失調症の治療に使用される第二世代の抗精神病薬であり、この研究は、経皮吸収型BNSテープ製剤(BNSテープ)の急性増悪統合失調症患者における有効性、安全性および薬物動態を無作為化割付け二重盲検多施設共同プラセボ対照比較第3相試験で実施した。また、本試験に引続き非盲検継続長期試験を実施したが、本論文の内容は二重盲検期の内容に限定し、非盲検継続長期試験の内容は別途、報告した。なお、本論文は[Schizophrenia Research ePubli...
お知らせ・マニュアル
医学部
